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Aim: The purpose of this study was to evaluate LVP1 and correlate them with MLD2 and
V203 in the lobes of the lung.
Background: Radiation-induced lung injury after breast irradiation is controversial. The inci-
dence of such an injury could have negative consequences on breast cancer patients.
Materials and Methods: Twenty-three women treated with Breast-conserving surgery,
chemotherapy, and locoregional RT4 underwent body plethysmography pre-RT and 3 and
6  months post-RT. Statistical analysis was used to evaluate LVP over time and relate them
with  MLD, V20, age, and concurrent hormonal therapy.
Results: LVP decreased after 3 months and then showed a slight improvement by return-
ing  partially to their pre-RT values after 6 months. The mean LVP was −0.64% for one
Gy  increase of MLD and −0.34% for one percent increase of V20 after 3 months. After 6
months, only VC5 showed 0.45% reduction with MLD in the upper lobe. Finally, there was no
significant correlation between LVP with respect to age and concurrent hormonal therapy.
Conclusions: The results of this study showed that lung volume changes were not a cause for
concern in breast cancer patients. There are three reasons to support this conclusion. Lungvolume changes and percentage reductions in LVP for each Gy increase of MLD  and each
percentage increase of V20 in each lobe were small; patients were asymptomatic during the
follow-up period; and LVP
©  2019 Greater Po
∗ Corresponding author.
E-mail addresses: m abdemanafi@yahoo.com (M. Abdemanafi), mbt
(A. Akhavan), I.abedi@med.mui.ac.ir (I. Abedi).
1 Changes in lung volume parameters
2 Mean lung dose




1507-1367/© 2019 Greater Poland Cancer Centre. Published by Elsevier  showed partial improvements after 6 months.land Cancer Centre. Published by Elsevier B.V. All rights reserved.
avakoli@mui.ac.ir (M.B. Tavakoli), ali52akhavan@yahoo.com
















































reports of practical oncology and 
.  Background
reast cancer is the most common type of malignancy in
emales. Nowadays, breast cancer is often detected at an early
tage and managed with surgery, RT6 and systemic therapy.1,2
djuvant radiotherapy following BCS7 is a well-established
reatment, resulting in decreased local and loco-regional
ecurrence and mortality rates.3 Chemotherapy, on the other
and, reduces the rate of disease progression and is gen-
rally offered to women with the involvement of axillary
ymph nodes, large tumor size, high-grade histological type,
nd extensive lymphovascular permeation.4 During radiother-
py, a larger part of the lung is typically included within the
adiation field and may result in lung toxicity.5 Radiation-
nduced lung injury is usually presented with two distinct
linical stages: radiation pneumonitis (developing 1–6 months
ost-RT) and fibrosis (developing from 6 months onward).6
he probability and severity of early and late pulmonary
amage are related to factors such as total radiation dose,
rradiated volume7 and radiotherapy techniques.8,9 However,
ulmonary function is not only limited by the previously
entioned factors, and is also affected by some clinical fac-
ors such as chemotherapy,6 smoking10 and pre-treatment
ulmonary function.9 The correlation between lung volume
hanges with tamoxifen and letrozole was studied previously.
ome studies showed increased rates of lung fibrosis with con-
urrent tamoxifen and RT.11,12 However, other studies showed
hat concurrent hormonal therapy neither influenced disease
ontrol or survival rate nor increased the risk of pulmonary
brosis.13,14 Therefore, the relationship between lung fibrosis
nd concurrent hormonal therapy is still a matter of debate.
Several authors attempted to assess the relationship
etween irradiated lung volume and radiation dose with
FTs8 in patients with breast cancer,15 malignant lymphoma16
nd lung cancer.17 Moreover, some studies analyzed the
nfluence of treatment-related factors such as age, gender,
moking, chemotherapy and MLD9.6,10 A number of other pub-
ished studies assessed pulmonary changes and correlated
hem with dose-volume parameters by using PFTs and high-
esolution computed tomography.15,18
.  Aim
n the present study, lung volume changes of the breast cancer
atients were evaluated with body plethysmography, pre-RT
nd 3 and 6 months post-RT, and their correlation with MLD
nd V2010 were studied in the upper and lower lobes of the
ung. The reason for separating the lobes of the lung in this
tudy was the difference between each lobe and the variation
n the V11 /Q12 ratio at the apex and base of the lung.19 Pul-
6 Radiation Therapy
7 Breast Conserving Surgery
8 Pulmonary Function Tests
9 Mean Lung Dose
10 The percentage of lung volume receiving 20 Gy
11 Ventilation
12 Perfusiontherapy 2 4 ( 2 0 1 9 ) 556–562 557
monary symptoms of the patients i.e. cough, dyspnoea, and
fever were assessed using a questionnaire, following Common
Terminology Criteria for Adverse Events (version 3.0).20
3.  Materials  and  methods
3.1.  Study  design
Twenty-three consecutive women with T1-T2 and node-
positive breast cancer undergoing BCS and at least six cycles of
chemotherapy with anthracycline- and/or taxane-containing
regimens were incorporated in this study from January to
August 2018. The average age was 48 years (ranging between 32
and 62), and the majority of the cohort (14 patients; 61%) had
left-side breast cancer. The inclusion criteria were histologic
evidence of breast cancer, female gender, and non-smokers.
The exclusion criteria were previous chronic respiratory or
heart disease, history of collagen vascular disease, and recur-
rence of breast cancer or distant metastasis. Of  all the patients,
65% received concurrent hormonal therapy with tamoxifen
(60%) and letrozole (40%) concurrently with RT. A written
informed consent was obtained from the patients before
inclusion in the study.
3.2.  CT-simulation
CT simulation of the patients was carried out by a 64-slice
MDCT13 covering the entire thoracic region from the skull base
to 3 cm below the breast with 5-mm slice thickness and 5-mm
interval.
3.3.  Contouring
The target and OAR were contoured according to the crite-
ria of the International Commission on Radiation Units and
Measurements Reports 50 and 6221 and RTOG breast contour-
ing atlas.22 Dose-volume constraints in patients treated with
locoregional RT were defined as V20 of the lung <35%.23 The
ipsilateral lung was divided into its lobes (upper and lower),
and each lobe was contoured separately. The right middle
lobe was included in the right lower lobe. The data were then
imported to the TiGRT, a 3D-radiation therapy treatment plan-
ning system.
3.4.  Radiation  therapy
Three-dimensional conformal radiotherapy plans were cre-
ated. All the patients received locoregional RT with a Siemens
Primus linear accelerator consisting of two tangential fields
and two supraclavicular fields designed for each patient, as
shown in Fig. 1. Half-beam blocking was used to avoid over-
dosing or underdosing at the junction of the fields and dose
inhomogeneity.A total dose of 50 Gy to the PTV along with 50 Gy to the axil-
lary and supraclavicular fossa was delivered in 2 Gy/fraction,
5 days/week, using 6-MV photon beams. A boost dose of 10 Gy
13 Multi-detector computed tomography
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Fig. 1 – Planning and dose distribution in axial (top), coronal (left) and sagittal (right) views. Treatment planning of a
random patient receiving 3-D conformal RT for breast and supraclavicular fields.
vious values in percentages 3 (LVP3) and 6 months (LVP6)
post-RT.was given to the tumor bed of all the patients with the same
fractionation and energy. Wedges were used to reduce dose
inhomogeneity.24
3.5.  Body  plethysmography
For each patient, measurements of dynamic and static lung
volumes were carried out by a body plethysmograph (ZAN-
500, nSpire Health GmbH Germany). Vital capacity (VC) and
forced vital capacity (FVC) measure lung volumes in litres.25
Forced expiratory volume in one second (FEV1) is a mechan-
ical property of large and medium-sized airways (bronchi).
Residual volume (RV) is the volume of air remaining in the
lungs after full exhalation. Total lung capacity (TLC) is a
total amount of respiratory volume. Maximum expiratory
flow (MEF) is a sensitive measure of small airways (bronchi-
oles) and can be used as a diagnosis for obstructive lung
disease.26According to clinical findings, the GOLD14 concluded that
for detection and classification of lung diseases, FEV1/FVC had
higher sensitivity whereas FEV1/VC had higher accuracy.27
Therefore, we considered the analysis of Mirsadraee et al.,28
who recommended to report both FEV1/FVC and FEV1/VC
values and choose the best result according to clinical
findings.
The test was performed pre-RT and 3 and 6 months
post-RT using the same technique and equipment for all
the patients. All the measurements were expressed as a
percentage of the predicted value adjusted for age, gender,
weight, and height. Changes in LVP15 were expressed as the
difference between pre- and post-RT values divided by pre-14 Global Initiative for Chronic Obstructive Lung Disease
15 Lung Volume Parameters
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Table 1 – Characteristics of the study population.
Variables N (%)
Age(y)
Mean (Range) 48 (32–62)







Invasive Ductal Carcinoma 21 (91%)






































Fig. 2 – Changes in the mean LVP 3 and 6 months post-RT
relative to pre-RT values as a percentage of pre-RT valuescontaining
regimens
.6.  Statistical  analysis
he paired sample t-test was used to compare the average
LD  and V20 in the lobes of the lung and analyze LVP over
ime. Moreover, the repeated measures ANOVA (RM-ANOVA)
as used to compare the mean LVP (as percentages of normal
alues adjusted for age, weight, and height) during the study
eriod. However, LSD16 was used for the two-by-two compar-
son of the mean LVP pre-RT and 3 and 6 months post-RT.
urther, linear regression analysis was performed to assess
he relationship between irradiated lung volume and absorbed
ose by each lobe of the lung, derived from DVHs, taking LVP3
nd LVP6 as dependent values and MLD  and V20 as inde-
endent variables. The Pearson correlation was performed to
tudy the correlation between age and LVP. A correlation
etween positive or negative hormone receptors and LVP
as observed by the independent t-test. All statistical anal-
ses were carried out using SPSS 22.0 (SPSS, Chicago, IL, USA).
 P-value of 0.05 was considered statistically significant.
.  Results
emographic characteristics, T-stage, histological types, hor-
one receptors, and chemotherapy regimens in the study
opulation are presented in Table 1.
.1.  DVH-data
he paired sample t-test showed statistically significant dif-
erences in both MLD  and V20 in the upper and lower lobes
f the lung (P < 0.001). The average MLD  was 21.62 Gy (SD 5.45)
nd 4.28 Gy (SD 2.20) in the upper and lower lobe of the lung,
espectively. Moreover, the average V20 was 42.28% (SD 10.8)
nd 6.68% (SD 4.41) in the upper and lower lobe of the lung,
16 Least significant difference(LVP3 and LVP6).
respectively. The average MLD and V20 values of the upper lobe
were twice the MLD and V20 values of the entire lung (12.09 Gy
and 22.87%). However, the average MLD  and V20 values in the
lower lobe were almost one third of the MLD  and V20 values
of the entire lung.
4.2.  Outcomes  of  body  plethysmography  over  time
A comparison between LVP with their standard deviation
and minimum/maximum values is shown in Table 2. Sig-
nificant changes were observed in the mean percentages of
VC, FVC, FEV1, and FEV1/FVC, TLC and RV. The LSD analysis
showed statistically significant between-group differences in
VC, FVC, FEV1, TLC, and RV between pre-RT and 3 months
post-RT and pre-RT and 6 months post-RT and in FEV1/FVC
between pre-RT and 3 months post-RT. However, none of the
parameters showed any significant difference between 3 and
6 months post-RT.
Fig. 2 shows LVP3 and LVP6 over time. All the param-
eters except for FEV1/VC and FEV1/FVC decreased 3 months
post-RT. The major descent was related to FVC with the mean
equal to −7.78% (SD = 4.37). Six months post-RT, FEV1 and RV
continued to decrease at a slower rate, FEV1/VC and FEV1/VC
decreased but remained within their normal range (between
80–120%), and the rest of the parameters increased partially.
An association between LVP with MLD  (Gy) and V20 (%)
is: LVP3 or LVP6 = (0) * MLD or V20 ± constant. The slope of
the regression analysis is 0 and the constant in the equations
is ignored by considering that only RT brings about changes in
LVP. The results are shown in Table 3.
4.3.  Correlation  between  LVP  with  MLD  and  V20
Three months post-RT, VC, FVC, and TLC showed statis-
tically significant correlation with MLD  and V20. The mean
reduction in LVP ranged from 0.39% to 0.84% for each Gy
increase of MLD and from 0.28% to 0.42% for each percent-
age increase of V20. Six months post-RT, only VC reached a
significant level and showed a reduction of 0.45% per each Gy
increase of MLD in the upper lobe. The correlation between
VC and each Gy increase of MUD in the upper lobe, the entire
lung, and the lower lobe 3 months post-RT is shown in Fig. 3.
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Table 2 – Changes of the mean LVP.
Percentage of the predicted values































































∗ Abbreviations: VC, vital capacity; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; MEF, maximum expiratory flow;
TLC, total lung capacity; RV, residual volume.
∗∗ Analysis of variance for repeated measurements (RM-ANOVA). Statistically significant values are in boldface type.
∗∗∗ Mean values expressed as percentages of predicted values adjusted for age, gender, and height with the standard deviation in parentheses.
Table 3 – Correlation between LVP with MLD  and V20 in each lobe and the entire lung.
Independent variables Units Upper lobe* P-value Entire lung P-value Lower lobe P-value
(VC3 / MLD**) ±SE (%/Gy) −0.92 ± 0.38 <0.001 −0.63 ± 0.23 0.014 −0.58 ± 0.32 0.125
(VC3 / V20***) ±SE (dimensionless) −0.42 ±  0.06 0.001 −0.23 ± 0.17 0.021 −0.20 ± 0.10 0.036
(VC6 / MLD) ±SE (%/Gy) −0.45 ± 0.25 0.009 −0.43 ± 0.63 0.135 −0.29 ± 0.46 0.339
(VC6 / V20) ±SE (dimensionless) −0.32 ± 0.32 0.145 −0.20 ± 0.32 0.188 −0.15 ± 0.19 0.433
(FVC3 / MLD)±SE[0±SE] (%/Gy) −0.60 ± 0.41 0.025 −0.45 ± 0.29 0.135 −0.38 ± 0.15 0.156
(FVC3 / V20) ±SE (dimensionless) −0.31 ± 0.08 0.014 −0.21 ± 0.21 0.150 −0.16 ± 0.12 0.178
(TLC3 / MLD) ±SE (%/Gy) −0.99 ± 0.21 0.016 −0.78 ± 0.25 0.005 −0.39 ± 0.50 0.06
(TLC3 / V20) ±SE (dimensionless) −0.54 ± 0.09 <0.001 −0.41 ± 0.08 <0.001 −0.37 ± 0.18 0.048
Statistically significant values are in boldface type.
∗∗ The slope of the regression line (0) with each percent increase in MLD ± SE (standard error).
∗∗∗ The slope of the regression line with each percent increase of V20.
Fig. 3 – VC3 relative to each Gy increase of MLD  in the upper lobe (circle dots), the entire lung (square dots), and the lower
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ther possible factors for developing lung disorders are age
nd hormonal therapy. However, in this study, no significant
ssociation was observed between these two variables and
LVP.
.  Discussion
 number of studies described lung volume changes in
reast cancer patients undergoing different treatment modal-
ties by comparing local and locoregional RT, different
adiotherapy fractioned regimens, or different chemother-
py regimens.15,18,26 Moreover, few studies assessed lung
olume changes using body plethysmography,18,26 which
easures static lung volumes accurately (VC, TLC, and RV)
nd leads to a better diagnosis of restrictive or obstructive
iseases.29
In the present study, patients with similar treatment pro-
edures underwent body plethysmography pre-RT and 3 and
 months post-RT. Changes in LVP were assessed, and the
orrelation between LVP with MLD  and V20 was studied
n the upper lobe, the entire lung, and the lower lobe. To
ur knowledge, this was the first study separating the upper
nd lower lobes of the lung. The reason for considering
he lobes of the lung separately was the difference between
he lobes and the variation of the V/Q ratio throughout
he lung.
The results of this study showed that 3 months post-RT,
EV1/VC and FEV1/FVC remained within 80% and 120% of the
redicted values while VC, FVC, FEV1, and TLC were reduced.
hese changes are indicative of a restrictive lung disorder. The
ecrease in MEF  25–75% might represent damage to bronchi-
les, which leads to obstructive lung disease.4 However, as MEF
5–75% did not significantly change in our study, the probabil-
ty of restrictive lung disease increased.
The results also revealed that 6 months post-RT, FEV1 and
V decreased at a slower rate. The small increase in VC, FVC,
EF  25–75%, and TLC could indicate more  probable improve-
ents in LVP over a longer follow-up duration. None of the
atients showed any RT-induced respiratory symptoms at the
ime of the study.
The results of this study were consistent with previous
tudies6,13,26 in that LVP was reduced significantly 3 months
ost-RT and was partially recovered 6 months post-RT. Jaen
t al.30 reported lung volume changes in breast cancer patients
t 7 years. They concluded that DLCO, ventilation, and perfu-
ion reduced up to 2 years post-RT and partially recovered at 7
ears. However, FVC and FEV1 reduced 6 months post-RT and
eached their baseline values at 7 years.
Average MLD  and V20 were greater in the upper lobe
han in the entire lung and the lower lobe. Consequently,
he mean LVP for each Gy increase of MLD and each per-
entage increase of V20 were greater in the upper lobe than
n the entire lung and the lower lobe. This result was also
xpected by the higher V/Q ratio in the apex of the lung.
owever, the mean LVP for each Gy increase of MLD and
ach percentage increase of V20 were obtained <1% in the
pper lobe. Similarly, other researchers reported very small
hanges in LVP with respect to MLD  and V20 over time. Jaén
t al.13 obtained a regression equation between the relativetherapy 2 4 ( 2 0 1 9 ) 556–562 561
reduction of perfusion and V,10–20 a percentage of irradiated
lung volume receiving a dose between 10 and 20 Gy, as follows:
perfusion = −1.43 × pV.10–20 Moreover Theuws et al.10 found
a correlation between pulmonary changes pre- and post-RT
and MLD in breast cancer and malignant lymphoma patients.
The relative decrease in the LVP (VC, FVC, and FEV1) for
each Gy increase of MLD  ranged from 0.8% to 0.9% 3 months
post-RT and from 0.3% to 0.4% 18 months post-RT. However,
Goldman et al.31 and Dehing-Oberije et al.32 could not detect
a correlation between ipsilateral V20 and VC and MLD  with
FVC, FEV1, and DLCO, respectively.
In the current study, no correlation was observed between
age and concurrent hormonal therapy with LVP 3 and
6 months post-RT. Similar results were reported by other
researchers.13,26
Determination of a more  definitive threshold value for V20
in both the upper and lower lobes of the lung concerning lung
fibrosis requires a longer follow-up duration and a larger sam-
ple size. It is best to carry out additional tests such as DLCO
to better detect pulmonary disorders and their severity over
time and also to predict a more  accurate model for LVP.
According to the obtained results, in cases where a greater
part of the ipsilateral lung is exposed and consequently V20
exceeds 35%, we  suggest separating the upper and lower lobes
of the lung and calculating V20 for each lobe separately. If
V20 is below 42% in the upper lobe (average V20 in the upper
lobe) and is not above 6% in the lower lobe (average V20 in the
lower lobe), it does not appear to have a major impact on lung
volume changes.
6.  Conclusion
Radiotherapy can cause lung volume changes. However, as
percentage reductions in LVP for each Gy increase of MLD  and
each percentage increase of V20 in the upper and lower lobes
are small and patients are completely asymptomatic during
a follow-up period as observed in our study, lung volume
changes will not be a cause for concern.





This work was supported by the Isfahan University of Medical
Sciences [grant number 396959]. We  sincerely thank the staff
of the RT Department in Isfahan hospital for their help and
support during this project. We  also thank A. Hassanzadeh,


























562  reports of practical oncology an
 e  f  e  r  e  n  c  e  s
1. Overgaard M, Christensen JJ, Johansen H, Nybo-Rasmussen A,
Brincker H, et al. Postmastectomy irradiation in high-risk
breast cancer patients: present status of the Danish Breast
Cancer Cooperative Group trials. Acta Oncol 1988;27(6):707–14.
2. Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S,
Skoog L, et al. Radiotherapy, chemotherapy, and tamoxifen as
adjuncts to surgery in early breast cancer: a summary of
three randomized trials. Int J Radiat Oncol Biol Phys
1989;16(3):629–39.
3. Whelan TJ. Use of conventional radiation therapy as part of
breast-conserving treatment. J Clin Oncol 2005;23(8):1718–25.
4. Spyropoulou D, Leotsinidis M, Tsiamita M, Spiropoulos K,
Kardamakis D. Pulmonary function testing in women with
breast cancer treated with radiotherapy and chemotherapy.
In  vivo 2009;23(5):867–71.
5. Lind PA, Gagliardi G, Wennberg B, Fornander T. A descriptive
study of pulmonary complications after postoperative
radiation therapy in node-positive stage II breast cancer. Acta
Oncol 1997;36(5):509–15.
6. Theuws JC, Kwa SL, Wagenaar AC, Seppenwoolde Y, Boersma
LJ, Damen EM, et al. Prediction of overall pulmonary function
loss in relation to the 3-D dose distribution for patients with
breast cancer and malignant lymphoma. Radiother Oncol
1998;49(3):233–43.
7. Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider J,
et  al. Tolerance of normal tissue to therapeutic irradiation. Int
J  Radiat Oncol Biol Phys 1991;21(1):109–22.
8. Wennberg B, Gagliardi G, Sundbom L, Svane G, Lind P. Early
response of lung in breast cancer irradiation: radiologic
density changes measured by CT and symptomatic radiation
pneumonitis. Int J Radiat Oncol Biol Phys 2002;52(5):1196–206.
9. Lind PA, Wennberg B, Gagliardi G, Fornander T. Pulmonary
complications following different radiotherapy techniques
for breast cancer, and the association to irradiated lung
volume and dose. Breast Cancer Res Treat 2001;68(3):199–210.
0. Theuws JC, Muller SH, Seppenwoolde Y, Kwa SL, Boersma LJ,
Hart GA, et al. Effect of radiotherapy and chemotherapy on
pulmonary function after treatment for breast cancer and
lymphoma: A follow-up study. J Clin Oncol
1999;17(10):3091–100.
1. Bentzen SM,  Skoczylas JZ, Overgaard M, Overgaard J.
Radiotherapy-related lung fibrosis enhanced by tamoxifen.
JNCI 1996;88(13):918–22.
2. Yavas G, Yavas C, Acar H, Toy H, Yuce D, Ata O. Comparison of
the effects of aromatase inhibitors and tamoxifen on
radiation-induced lung toxicity: results of an experimental
study. Support Care Cancer 2013;21(3):811–7.
3. Jaén J, Vázquez G, Alonso E, León A, Guerrero R, Almansa JF.
Changes in pulmonary function after incidental lung
irradiation for breast cancer: A prospective study. Int J Radiat
Oncol Biol Phys 2006;65(5):1381–8.
4. Bourgier C, Kerns S, Gourgou S, Lemanski C, Gutowski M,
Fenoglietto P, et al. Concurrent or sequential letrozole with
adjuvant breast radiotherapy: final results of the CO-HO-RT
phase II randomized trial. Ann Oncol 2015;27(3):474–80.
5. Hardman P, Tweeddale P, Kerr G, Anderson E, Rodger A. The
effect of pulmonary function of local and loco-regional
irradiation for breast cancer. Radiother Oncol 1994;30(1):33–42.
6. Smith LM, Mendenhall NP, Cicale MJ, Block ER, Carter RL,
Million RR. Results of a prospective study evaluating the
3
iotherapy 2 4 ( 2 0 1 9 ) 556–562
effects of mantle irradiation on pulmonary function. Int J
Radiat Oncol Biol Phys 1989;16(1):79–84.
7. Choi NC, Kanarek DJ. Toxicity of thoracic radiotherapy on
pulmonary function in lung cancer. Lung Cancer 1994;10.
S219-S30.
8. Lind PA, Rosfors S, Wennberg B, Glas U, Bevegård S,
Fornander T. Pulmonary function following adjuvant
chemotherapy and radiotherapy for breast cancer and the
issue of three-dimensional treatment planning. Radiother
Oncol 1998;49(3):245–54.
9. Galvin I, Drummond G, Nirmalan M.  Distribution of blood
flow and ventilation in the lung: gravity is not the only factor.
Br J Anaesth 2007;98(4):420–8.
0. Dean E. Effect of body position on pulmonary function. Phys
Ther 1985;65(5):613–8.
1. Washigton D. International Commission on Radiation Units
and Measurements: ICRU Report 62. In: Prescribing, Recording
and  Reporting Photon Beam Therapy.; 1999.
2. Group RTO. Breast cancer atlas for radiation therapy
planning: consensus definitions. In: Breast cancer atlas for
radiation therapy planning: consensus definitions.; 2015. Available
from: http://wwwrtogorg/CoreLab/ContouringAtlases/
BreastCancerAtlasaspx.
3. Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavicic V,
Jakobsen EH, et al. Delineation of target volumes and organs
at risk in adjuvant radiotherapy of early breast cancer:
national guidelines and contouring atlas by the Danish Breast
Cancer Cooperative Group. Acta Oncol 2013;52(4):703–10.
4. Aref A, Thornton D, Youssef E, He T, Tekyi-Mensah S, et al.
Dosimetric improvements following 3D planning of
tangential breast irradiation. Int J Radiat Oncol Biol Phys
2000;48(5):1569–74.
5. Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi
R,  et al. Interpretative strategies for lung function tests. Eur
Respir J 2005;26(5):948–68.
6. Krengli M, Sacco M, Loi G, Masini L, Ferrante D, Gambaro G,
et  al. Pulmonary changes after radiotherapy for conservative
treatment of breast cancer: a prospective study. Int J Radiat
Oncol Biol Phys 2008;70(5):1460–7.
7. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS.
Global strategy for the diagnosis, management, and
prevention of chronic obstructive pulmonary disease:
NHLBI/WHO Global Initiative for Chronic Obstructive Lung
Disease (GOLD) Workshop summary. Am J Respir Crit Care Med
2001;163(5):1256–76.
8. Mirsadraee M, Salarifar E, Attaran D. Evaluation of
Superiority of FEV1/VC Over FEV1/FVC for Classification of
Pulmonary Disorders. J Cardiovasc Med 2015;3(4):355–9.
9. Lutfi MF. The physiological basis and clinical significance of
lung volume measurements. Multidiscip Respir Med
2017;12(1):3.
0. Jaén J, Vázquez G, Alonso E, Maria D, Díaz L, De Las Heras M,
et  al. Long-term changes in pulmonary function after
incidental lung irradiation for breast cancer: a prospective
study with 7-year follow-up. Int J Radiat Oncol Biol Phys
2012;84(5), e565-e70.
1. Blom Goldman U, Svane G, Anderson M, Wennberg B, Lind P.
Long-term functional and radiological pulmonary changes
after radiation therapy for breast cancer. Acta Oncológica
2014;53(10):1373–9.2. Dehing-Oberije C, De Ruysscher D, van Baardwijk A, Yu S,
et  al. The importance of patient characteristics for the
prediction of radiation-induced lung toxicity. Radiother Oncol
2009;91(3):421–6.
